UPPTHERA and ComInnex sign research collaboration for the development of novel Proteolysis-Targeting Chimera candidatesBUDAPEST, Hungary and SEOUL, South Korea, May 04, 2021 (GLOBE NEWSWIRE) UPPTHERA, a pharmaceutical venture company aiming for new drugs based on targeted protein degradation (TPD) technology and.
Share:
BUDAPEST, Hungary and SEOUL, South Korea, May 04, 2021 (GLOBE NEWSWIRE) UPPTHERA, a pharmaceutical venture company aiming for new drugs based on targeted protein degradation (TPD) technology and ComInnex, a specialist chemistry group with expertise in the design and synthesis of small molecules for drug discovering will accelerate the development of new proteolysis targeting chimeras (commonly known as PROTAC) or Molecular Glues. Within the framework of the collaboration, UPPTHERA and ComInnex will co-verify a number of potential novel E3 ligase ligands which have been designed by ComInnex and co-develop TPD chimera molecules to which the novel E3 ligase ligands will be applied. After that, UPPTHERA will manage downstream development (pre-clinical & clinical trials) of the Targeted Protein Degradation pipeline. The chemistry and biology assays will be developed and performed by UPPTHERA whilst ComInnex will perform all chemistry aspects of synthesis, optimization and scal
BUDAPEST, Hungary and SEOUL, South Korea, May 04, 2021 (GLOBE NEWSWIRE) UPPTHERA, a pharmaceutical venture company aiming for new drugs based on targeted protein degradation (TPD) technology and ComInnex